Outcome of Patients Treated With ECLS

Heart Failure Clinical Trial

Official title:

Outcome of Patients Treated With Extracorporeal Life Support

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04405817
• Other study ID #: ECLS-Jsph
• Status: Recruiting
• Start date: January 1, 2012
• Est. completion date: December 31, 2025

Study information

• Verified date: May 2020
• Source: Nanjing Medical University
• Contact: Hong Liu, MD
• Phone: 18801281613
• Email: DR.HONGLIU[@]FOXMAIL.COM
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Extracorporeal life support (ECLS), also called extracorporeal membrane oxygenation (ECMO), is an extracorporeal technique of providing effective circulatory and (or) respiratory failure, with a growing number of critically ill patients benefit from it. The aim of this study is to investigate the outcome of patients treated With ECMO, and to evaluate the short-term and long-term outcomes of patients with ECLS.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Gender: All
• Age group: 1 Year to 100 Years

Eligibility

Inclusion Criteria:

• Patients receiving ECMO for circulatory and/or respiratory support

Exclusion Criteria:

• Refusal of consent

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• Acute Respiratory Failure
• Cardiac Arrest
• Cardiogenic Shock
• Heart Failure
• Respiratory Distress Syndrome, Adult
• Respiratory Distress Syndrome, Newborn
• Respiratory Insufficiency
• Shock, Cardiogenic

Intervention

Device:
• ECMO
ECMO for circulatory and/or respiratory support

Locations

Country	Name	City	State
China	The first affiliated hospital of nanjing medical university	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite of death from any cause, resuscitated circulatory arrest, and implantation of another mechanical circulatory support device		30 days after ECMO implantation
Secondary	All-cause mortality		30 days after ECMO implantation
Secondary	All-cause mortality		12 months after ECMO implantation